PriceTargets.com logo

Upstream Bio - UPB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.50
  • Forecasted Upside: 248.55%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$16.21 As of 12/20/2024 06:16 PM ET
▼ -0.4 (-2.41%)

This chart shows the closing price for UPB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Upstream Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UPB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UPB

Analyst Price Target is $56.50
▲ +248.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Upstream Bio in the last 3 months. The average price target is $56.50, with a high forecast of $75.00 and a low forecast of $38.00. The average price target represents a 248.55% upside from the last price of $16.21.

This chart shows the closing price for UPB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Upstream Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024Piper SandlerInitiated CoverageOverweight$75.00
11/5/2024JPMorgan Chase & Co.Initiated CoverageOverweight$38.00
11/5/2024William BlairInitiated CoverageOutperform
11/5/2024TD CowenInitiated CoverageBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Upstream Bio logo
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $16.21
Low: $15.51
High: $17.06

50 Day Range

MA: $22.80
Low: $16.11
High: $27.39

52 Week Range

Now: $16.21
Low: $14.97
High: $29.46

Volume

3,884,049 shs

Average Volume

370,503 shs

Market Capitalization

$868.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Upstream Bio?

The following Wall Street analysts have issued stock ratings on Upstream Bio in the last twelve months: JPMorgan Chase & Co., Piper Sandler, TD Cowen, and William Blair.
View the latest analyst ratings for UPB.

What is the current price target for Upstream Bio?

0 Wall Street analysts have set twelve-month price targets for Upstream Bio in the last year. Their average twelve-month price target is $56.50, suggesting a possible upside of 248.6%. Piper Sandler has the highest price target set, predicting UPB will reach $75.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $38.00 for Upstream Bio in the next year.
View the latest price targets for UPB.

What is the current consensus analyst rating for Upstream Bio?

Upstream Bio currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UPB will outperform the market and that investors should add to their positions of Upstream Bio.
View the latest ratings for UPB.

What other companies compete with Upstream Bio?

Other companies that are similar to Upstream Bio include Prestige Consumer Healthcare, Avidity Biosciences, Organon & Co., PTC Therapeutics and Perrigo. Learn More about companies similar to Upstream Bio.

How do I contact Upstream Bio's investor relations team?

Upstream Bio's physical mailing address is 890 Winter Street, Suite 200, Waltham, MA 02451, United States. The company's listed phone number is (781) 208-2466. The official website for Upstream Bio is upstreambio.com. Learn More about contacing Upstream Bio investor relations.